Critical analysis of phase II and III randomised control trials (RCTs) evaluating efficacy and tolerability of a ß3-adrenoceptor agonist (Mirabegron) for overactive bladder (OAB). (2015)

First Author: Rossanese M

Attributed to: MRC Centre for Transplantation funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1111/bju.12730

PubMed Identifier: 24602031

Publication URI: http://europepmc.org/abstract/MED/24602031

Type: Journal Article/Review

Volume: 115

Parent Publication: BJU international

Issue: 1

ISSN: 1464-4096